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Common data elements for secondary use
of electronic health record data for clinical
trial execution and serious adverse event
reporting
Philipp Bruland1* , Mark McGilchrist2, Eric Zapletal3, Dionisio Acosta4, Johann Proeve5, Scott Askin6,
Thomas Ganslandt7, Justin Doods1 and Martin Dugas1
Abstract
Background: Data capture is one of the most expensive phases during the conduct of a clinical trial and the
increasing use of electronic health records (EHR) offers significant savings to clinical research. To facilitate these
secondary uses of routinely collected patient data, it is beneficial to know what data elements are captured in
clinical trials. Therefore our aim here is to determine the most commonly used data elements in clinical trials and
their availability in hospital EHR systems.
Methods: Case report forms for 23 clinical trials in differing disease areas were analyzed. Through an iterative and
consensus-based process of medical informatics professionals from academia and trial experts from the European
pharmaceutical industry, data elements were compiled for all disease areas and with special focus on the reporting
of adverse events. Afterwards, data elements were identified and statistics acquired from hospital sites providing
data to the EHR4CR project.
Results: The analysis identified 133 unique data elements. Fifty elements were congruent with a published data
inventory for patient recruitment and 83 new elements were identified for clinical trial execution, including adverse
event reporting. Demographic and laboratory elements lead the list of available elements in hospitals EHR systems.
For the reporting of serious adverse events only very few elements could be identified in the patient records.
Conclusions: Common data elements in clinical trials have been identified and their availability in hospital systems
elucidated. Several elements, often those related to reimbursement, are frequently available whereas more specialized
elements are ranked at the bottom of the data inventory list. Hospitals that want to obtain the benefits of reusing data
for research from their EHR are now able to prioritize their efforts based on this common data element list.
Keywords: Clinical trials, Common data elements, Data quality, Electronic health records, Metadata, Secondary use
Background
Data collection is one of the most expensive processes
during the conduct of clinical trials. Over the last decade
the number of clinical trials and the size of trials have
steadily increased [1]. Likewise, the number and complexity
of case report forms (CRFs) capturing the data for trial sub-
jects grew as well. From a hospital perspective, the use of
electronic health record (EHR) systems and consequently
the number of patients having at least a basic electronic
medical record has experienced a significant and steady
growth [2]. The transition from paper-based to electronic
documentation has resulted in clinicians spending
around 25–30% of their time on electronic documenta-
tion tasks [3, 4].
Recent research has shown that a certain amount of
EHR data elements are available and suitable for differ-
ent research purposes [5–9]. Nevertheless, it is import-
ant to note that the provenance, availability, degree of
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standardization and structure of the EHR data plays a major
role in its re-use for clinical research purpose [10–12].
Currently, the exchange of routinely collected data be-
tween EHR systems and clinical research databases is
not fully automated and requires human intervention. This
manual step is time-consuming, error-prone and also de-
motivating [5]. Transferring data electronically from an
EHR source into an electronic data capture (EDC) system
in a systematic, auditable and unambiguous manner pro-
vides several advantages, avoiding the detrimental effects
of repeated data entry, decreasing documentation time and
improved data quality and cost-effectiveness [5, 7, 13, 14].
On-site data monitoring is an expensive process for
pharmaceutical companies as well. Monitors have to visit
all sites to perform the so-called’Source Data Verifica-
tion’ (SDV) by comparing source materials at the sites
with data that has been entered into the trial database,
e.g. an Electronic Data Capture (EDC) system. This tedi-
ous, time-consuming and expensive process might be
optimized through a connection between EHR systems
at the sites and the EDC system. If such a link is estab-
lished and presumed data are validated, SDV could likely
be reduced or even be eliminated. Time-consuming site
visits would be reduced to a minimum and the monitors
could focus on other aspects of the clinical trial conduct.
The Electronic Health Records for Clinical Research
(EHR4CR) project [15], which is funded by the Innova-
tive Medicines Initiative (IMI) has investigated these po-
tential incentives and benefits [16]. The project is a
public-private-partnership consisting of 34 partners from
European pharmaceutical industry and academic institu-
tions. Clinical partners were from France, Germany,
Poland, Switzerland, and the United Kingdom. The par-
ticipating companies from the European Federation of
Pharmaceutical Industries and Associations (EFPIA) were:
AMGEN, AstraZeneca, Bayer Health Care, F. Hoffmann-
La Roche Ltd, GlaxoSmithKline, Johnson & Johnson, Lilly,
MERCK KGaA, Novartis Pharma AG and Sanofi-Aventis.
The project’s aim was to develop methods and a soft-
ware platform as well as an accompanying business model
to support clinical trials based on routinely collected data
from EHR systems. Addressed scenarios included ‘proto-
col feasibility’, ‘patient identification and recruitment’,
‘clinical trial execution’ (CTE) and ‘serious adverse event
reporting’ (SAE). Disease areas which the project focused
on were diabetes, cardiovascular, infectious, oncology, neur-
ology and respiratory diseases. In addition to establishing
the benefits associated with the first two scenarios, the
‘business model’ workgroup also showed substantial poten-
tial savings in the scenario of ‘clinical trial execution’ [17].
The EHR4CR net benefits are obtained by offsetting
these savings against the expenditure for setting-up the
infrastructure to allow the re-use of routinely collected
clinical data. Suitable data elements need to be identified,
new structures for documentation procedures might have
to be established, and dedicated exports from the source
EHR to the research database have to be maintained. In
order to control and reduce these operational costs, the
best approach is to focus on the most frequently used data
elements of clinical trials.
The ability to pre-specify common data elements
(CDEs) would greatly improve the setup process of elec-
tronic databases and simplify the exchange of medical
data between different systems, i.e. EHR and EDC systems.
Subsequent analyses are then accelerated due to fewer data
transformations from different sources, and enhance the
comparability of outcomes. Additionally, CDEs might help
to reduce the number of, and focus on, relevant data ele-
ments that should be captured across all and in certain
therapeutic areas. These effects should be especially favor-
able in the context of multicenter trials that could benefit
from a common data model. Several initiatives and re-
search groups have tackled this issue and defined common
data elements for different therapeutic areas [18–22].
Common data elements are defined as metadata informa-
tion that is of interest or relevance in a specific research
domain. As part of the EHR4CR project, common data el-
ements for the scenarios of protocol feasibility and patient
identification and recruitment have previously been deter-
mined by Doods et al. [23, 24].
In order to re-use CDEs for clinical trials, they must
firstly be available for documentation in the EHR infor-
mation systems and secondly must be actively used to
contain patient data. Several research groups have exam-
ined the presence of clinical trial data elements within
existing EHR systems and found a broad range of coverage
between 13 to 70% [5–9]. However, these results were
only investigated for one clinical trial [5–7, 9] and an ana-
lysis of the frequency of documentation has so far only
been performed in very few cases (e.g. Botsis et al. [25]).
Nevertheless, it remains unclear what kind of data ele-
ments are most commonly required for the documenta-
tion of clinical trials and whether those elements are
available and also captured across EHR systems.
Objective
Work Package 7 (Pilots) of EHR4CR developed an inven-
tory of relevant data elements as an important corner-
stone for the development of a system facilitating the
secondary use of routinely collected data for the subject
documentation in clinical trial. An inventory also supports
calculations for business modeling to estimate whether
this approach is economically feasible. The aim of the
present research is to determine what data elements are
the most frequently used in clinical trial execution. An
additional focus was on data elements supporting SAE
reporting. The fundamental question is whether those
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data elements are covered by European EHR systems and
how frequently they have been captured.
Methods
An iterative consensus-driven approach was chosen for
creating the inventory of CDEs for CTE and SAE report-
ing as well as their completeness of documentation.
Material
CRFs from clinical trials were collected from all partici-
pating EFPIA companies within the EHR4CR project to
perform the analysis. Criteria for CRF selection were at
least one comprehensive clinical trial including over 200
study locations and a four-digit planned patient enrollment
number. According to the Good Clinical Practice guideline,
CRFs are understood as printed, optical or electronic docu-
ments designed to record all of the protocol-required in-
formation to be reported to the sponsor on each trial
subject [26]. A CRF consists of several forms, each one
with a different purpose/domain (e.g. demographics, vital
signs, adverse events, and also multiple instances of, some-
times unscheduled, follow-up forms). We analyzed 23 trials
covering the following disease areas as listed in table 1: car-
diovascular, diabetes, infectious, neurology, oncology, psy-
chiatric and respiratory. The reviewed clinical trial forms
ranged between 22 and 164 and contained in sum 1086
forms. We used all forms of a CRF for the analyses, also re-
peating and unscheduled ones. The most comprehensive
clinical trial amounted to a total of 3581 data elements.
The CRFs were in different computer processable for-
mats such as XML-based Operational Data Model from
the Clinical Data Interchange Standards Consortium
(CDISC) or Excel spreadsheet files. Apart from CDISC
Operational Data Model, all files were confirmed as
having different structures.
For the availability and completeness evaluation we
analyzed data exports from seven hospital sites for the
data inventory. Some sites provided data from hospital-
wide EHR systems while others only data from subsystems
or data warehouses, for instance specialized systems for
breast cancer or diabetes. For one site data was only avail-
able from in-patient cases.
Methodology
After collecting the trial CRFs, medical informatics profes-
sionals from academia and trial experts from EFPIA in the
EHR4CR project were involved in the consensus-driven
process for creating the data inventory. Data exports were
performed by different university hospitals across Europe
to assess the availability of these distinct elements and
their frequency of documentation.
Figure 1 illustrates the process and involved parties who
conducted the analyses for CTE and SAE reporting.
The following steps were performed:
1. Import: First, all collected CRFs were transformed
and loaded into the TMDB (Trial Master Database)
using the ETL-tool ‘Talend Open Studio for Data
Integration’ [27]. The TMDB is used to gather all
differently structured clinical trial CRFs together
within one structured database. Meta-information
for each trial is included concerning the disease area,
planned patient enrollment numbers and participating
sites. All CRFs and the associated data elements were
imported into the TMDB.
2. Form categorization: To determine a top list of
form, they need to be categorized by a domain,
which was allocated by trial experts from EFPIA,
each focusing on the trials provided by their
company. Domains are understood as topic-specific
classes (i.e. ‘medical history’, ‘vital signs’ or ‘concomi-
tant medications’) that deliver additional contextual
information to sites when exporting information on
data elements they hold. Where possible, we
assigned preferably the domains of CDISC’s SDTM
(Study Data Tabulation Model) [28], which is used
for the definition and transmission of trial data. For
instance, the form name ‘Coagulation Panel’ was
allocated with domain ‘Laboratory test results’ or
‘LB’ in SDTM.
3. Data element normalization: During form
categorization, data element names were normalized
using phonetic and word similarity measures such as
Levenshtein distance [29], Jaro-Winkler distance [30]
and Metaphone [31]. This was a relevant process for
the determination of common data elements. Special
characters and HTML tags as well as style sheet in-
formation were removed using regular expressions.
Measurement units were also removed since a
conversion of values is feasible. If CDISC variable
names were provided for an element, these names
were additionally used for the normalization of
element names. Finally, a manual review by trial
experts was conducted to validate this part of the
Table 1 Numbers of clinical trials and forms that were collected
per disease area
Disease area No. of trials Forms
Cardiovascular 3 158
Diabetes 3 172
Infectious 2 60
Neuroscience 1 64
Oncology 3 192
Psychiatric 1 69
Respiratory 10 371
Sum 23 1086
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process and determine results for those cases
which could not be matched.
4. Data element review: Forms are used to collect data
in clinical trials, therefore for the list of common
data elements we chose to first rank the form
domains by the frequency with which they appear in
CRFs. We removed form domains that only
appeared once. Then we calculated the frequency of
each unique data element within each form domain.
As a weighting factor we used the planned patient
enrollment numbers we had available for each trial.
There is an expectation that certain data elements
will be found in certain form domains and not in
others. Data elements within each form domain
were independently reviewed by two EFPIA trial
experts concerning an element’s relevance to the
associated form domain. Duplicates were detected
and CDISC variable names were added where
possible. If data elements relevant to the domain
were missing, the trial experts added them to the
particular form domain. Distinctions between
clinical parameters or administrative values (e.g.
sequence numbers, subject or site identifiers) were
also made to state whether data elements are
expected to be re-used from EHR systems. Due to
the association between form domains and data
elements, the frequency list for distinct CTE and
SAE elements could be created.
5. Consensus meeting: As a last step, we refined the
frequency lists in a face-to-face consensus meeting
at which academic as well as pharmaceutical partners
participated. The goal of this meeting was firstly to
discuss and vote about the allocated form domains,
data element names and semantic codes. It was stated
whether a form domain should be kept in the overall
list, whether an element should be removed in a form
domain, and, if so, whether the naming was correct,
whether it was a duplicate and finally which category
(clinical parameters or administrative values) it
belonged to. For instance, most elements that were
stated as irrelevant were removed. After this
consensus-driven step, the list was compared with the
previous data inventory of ‘patient identification and
recruitment’ to determine which elements had already
been examined at the data provider sites. Some sites’
health information systems or data warehouses
contained semantically annotated data elements. To
support the discovery, mapping and data export
Fig. 1 Process steps to create the data inventory for common data elements in clinical trials and their frequency of documentation in European
EHR systems. First, clinical trials were collected and imported into the trial master database (TMDB). Then forms were categorized into domains,
and all data elements were normalized. Top data elements per form domain were determined. Top form domains were reviewed by EFPIA
partners. Afterwards, at a face-to-face meeting all elements were jointly discussed with academia and pharmaceutical partners. Finally, clinical sites
identified element presence and performed data exports to determine the frequency of documentation
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process, semantic codes were assigned to the elements
in the list of the common data elements. Data elements
of many CRFs already contained SDTM codes, so
automated mappings to codes of the Unified Medical
Language System (UMLS) were performed. Elements
without SDTM codes were manually annotated by a
medical informatics professional and a medical expert.
SNOMED-CT (Systematized Nomenclature of
Medicine – Clinical Terms) codes were additionally
added through a semi-automated identification
process using the available mapping in the UMLS
database.
6. Presentation of frequency list: Finally, the CDE list
was distributed to the participating European
university hospitals within the EHR4CR consortium.
Data elements were located within structured
documentation of their local data warehouses
(previously populated with data from EHR systems),
EHR systems or specialized subsystems and the
frequency of occurrence was assessed, where
possible. Sites with semantically annotated data
sources programmatically identified matching entries
between the CDE list and their source system based
on identical results of code system codes. Frequency
was calculated using the number of entered values
which have been documented in the year 2013
divided by the total number of patients in 2013. To
address privacy concerns and to obtain comparable
values, relative percentages for a data element were
given. For instance, a frequency of 30.4% for
‘Bilirubin, total’ is the result of dividing the number
of entered values (9574) by the number of patients
in the year 2013 (31493). Where frequencies were
not calculated in figs. 2 and 3, a distinction was still
made between data elements that were ‘available’
(understood as possibility that the data element can
be stored in the EHR system) and ‘not available’ for
a given site. A heat map of data element frequency
was created to depict the whole data element
coverage, determined by the number of available
elements. The heat map for SAE elements was
reported separately. All analyses were performed
using Microsoft Excel.
Results
Data inventory
After the consensus meeting 14 form domains remained
relevant for potential pre-population in clinical trials.
Table 2 shows the final form domains used in clinical
trials with SDTM domain abbreviations where available
and the frequency of occurrence, number of total forms
and data elements that are contained in the respective
domain.
Medical History, Adverse Events, Laboratory and Dis-
position are ranked at the top. Apart from Surgery, Phys-
ical Examination and Tumor Response all domains were
present more than once in a clinical trial. SDTM domains
Fig. 2 Extract from the entire data inventory for clinical trial execution and SAE reporting. On the left-hand side the data elements and their form
domains are listed followed by the number of sites in which they occur and the sites availability. Site 1 and 2 used their data warehouse (DWH)
for element identification and exports
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could be identified for all forms apart from ‘Surgery’ and
‘Disease Characteristics’. As shown in table 2 domains like
‘Demographics’, ‘Medical History’, ‘Adverse Events’ and
‘Vital Signs’ are used in all trials; ‘Tumor response’ only in
one trial. The number of unique data elements which was
the basis of these analyses ranged between 27 in ‘Tumor
response’ and 2733 in ‘Adverse Events’.
After the consensus meeting the final data inventory
was created which contains 133 data elements that are
identified as the most frequently used elements in clinical
trials. In a comparison with the previous data inventory
for patient identification and recruitment 50 data elements
are identical and the remaining 83 elements are new for
the execution of clinical trials.
Availability and frequency in European EHR systems
Figure 2 presents an extract of the most frequently used
data elements in clinical trials sorted by the frequency of
captured elements in EHR systems. We differentiated be-
tween the presence (A=available; N/A=not available) and
the frequency of captured data elements. Demographic
and reimbursement data was ranked at the top of the list
followed by several laboratory test results. The number in
the right column indicates the frequency of occurrence in
all forms of all trials.
The complete data inventory can be accessed in the
additional material [see Additional file 1]. It also contains
semantic codes of the UMLS and where possible of
SNOMED CT as well as a definition of each data element.
Fig. 3 Common data elements for the reporting of SAEs. More than half of the data exporting sites have no SAE documentation available in their
EHRs. This refers to the items ‘seriousness’, ‘action taken’, and ‘autopsy report in case of death’. Some sites have few data elements available but
unclear whether data values are present apart from one where no data has been captured so far
Table 2 Consensus list of top 14 form domains in order of frequency of occurrence. This list also includes the SDTM domain
abbreviation if available and in how many trials the domain is used, the number of total forms and the containing data elements
Form domain SDTM domain In no. of trials No. of forms No. of data elements
Medical History MH 23 85 1336
Adverse Event AE 23 78 2733
Laboratory test results LB 10 75 1643
Disposition DS 19 74 653
Vital Signs VS 23 56 974
Concomitant Medications CM 22 52 1334
Questionnaire/Patient reported outcome QS 16 35 1122
Demographics DM 23 34 371
ECG EG 12 30 436
Disease Characteristics (ZC) 12 25 190
Substance Use SU 14 22 246
Surgery - 9 20 80
Physical Examination PE 5 10 33
Tumor response RS 1 7 27
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In terms of reporting SAEs, fig. 3 shows the most
frequently used data elements for the domain of SAEs.
Over half of the data providers reported not having
any documentation structure to collect SAE information
at all. Three reported that they have at least some ele-
ments available but it was unclear whether data has been
collected in 2013. Site 7 has a complete electronic docu-
mentation for SAEs available within their EHR, but has
never been used. Apart from the ‘date of death’, SAE re-
lated data has not been collected at all.
The complete inventory of data elements for ‘clinical trial
execution’ and ‘serious adverse event reporting’ can be
accessed online at: https://www.medical-data-models.org/
forms/17994.
Discussion
Re-use of routinely collected medical data is a promising
approach to some of the problems clinical trials currently
face. In most projects that attempt to use EHR data for
purposes other than patient care, the re-use requires man-
ual mapping between EHR and clinical trial data elements.
To keep these efforts to a minimum, it is desirable to
know which elements are most commonly used in clinical
trials, to what extent such elements are available in EHRs
and also to know how frequently such elements are cur-
rently documented.
The present research generated a list of common data
elements found in clinical trials. It was compiled through
an iterative and consensus-based process with medical in-
formatics professionals from academia and trial experts
from the European pharmaceutical industry. Through data
exports performed at different university hospitals across
Europe this list also presents the potential for re-use of
EHR data in clinical trials. Different source systems, lan-
guages and terminologies underline the complexity of this
research.
A large proportion of the data elements are laboratory
analytes that are commonly required in clinical trials.
These data elements are usually well structured within
EHR systems so that these elements could be identified.
During this localization process within the systems docu-
mentation structure it became apparent that some ele-
ments were present in multiple forms within the EHR. So,
the origin and purpose had to be clarified also with the aid
of the form domains and further semantic annotation. Es-
pecially the semantic annotation of data elements is a cru-
cial but also one of the most labor-intensive and tedious
tasks to be performed to facilitate the re-use of routinely
collected healthcare data. A further issue was that several
clinical concepts are only available in unstructured form
as free text in the EHR. Most frequently available are
demographic elements, captured by all hospitals followed
by diagnostic and procedural entities. The remaining data
elements are far less often captured, which is expected
since the main driver for data modeling in EHR systems is
support of regulation, policy and reimbursement rather
than clinical practice or research.
Since the CDE analysis did not focus on disease-
specific data elements, exports by certain departments
were not possible. Analyses for disease specific elements
might have resulted in higher frequency values because
disease-related elements are more frequently documented
in their disease area. Some data elements are common
between disease areas, whereas others do not belong to
the particular subset. For instance, biopsy results would
not exist in the cardiovascular disease area but rather
in oncology, and conversely for laboratory results in
cardiovascular disease. The site identification of these
data elements and their associated data exports was a
labor intensive and time consuming process for all partici-
pating sites. Conducting these analyses for elements in all
disease areas would increase the workload substantially
since data exports would need to be performed for each
element in each area separately; dependent on how
uniquely such elements are captured.
An additional focus of this work was to assess the
coverage of data elements for SAE reporting. Not sur-
prisingly, all clinical trials examined contained CRFs for
adverse events. Our analysis showed that elements are
highly standardized and also related to the SDTM do-
main of adverse events (AE). Nevertheless, apart from
‘date of death’ SAE elements such as start and end date,
outcome, verbatim description, severity and seriousness
or action(s) taken were not captured in the EHR system
at all. This underlines that clinical practice and trial exe-
cution are different conceptual domains with different
purposes for data capture.
However, it must be considered that some clinical
phenomenon may not be directly collected as a data elem-
ent but rather derived from different elements or different
perspectives. For instance,’cause of death’ might be related
to several finer grained data elements, such as biomarkers
being completely out of normal range. Although they
might be recorded, the ‘cause of death’ reported would be
determined by a forensic pathologist, which could be very
different from the perspective of a clinician. Hence, it
might be worthwhile to investigate further the data struc-
ture of information systems, the purpose of data elements
and the human rather than technical process of data
collection.
For the development of the data inventory we chose to
perform this process iteratively. This led us to a modi-
fied representation for the element list. In the previous
EHR4CR data inventories only the frequency was stated.
Instead, we decided to additionally indicate whether a
data element is just available regardless of whether its
frequency could be stated or not. A frequency of 0%
would imply that the data element is present but data
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were never collected. ‘Available’ gives the information
that data might have been captured but could not be
assessed.
Related work
In the EHR4CR project, data inventories for ‘protocol
feasibility’ [24] and ‘patient identification and recruit-
ment’ [23] have been performed by Doods et al. There,
75 data elements were identified for feasibility assess-
ment and 150 data elements for patient identification
and recruitment. Despite the differing scenarios, a com-
parison with the current inventory for the execution and
SAE reporting in clinical trials has shown that 50 data
elements have already been identified and 83 are new
data elements.
CDISC, C-Path, NCI-EVS and CFAST had introduced
an initiative on ‘Clinical Data Standards’ to create industry-
wide common standards for data capture in clinical trials
to support the exchange of clinical research and metadata
[32]. This initiative defines common data elements for
different therapeutic areas. Currently, traumatic brain
injury, breast cancer, COPD, diabetes, tuberculosis, etc.
are covered. In addition, the CDISC SDTM implemen-
tation guideline contains a set of standardized and struc-
tured data elements for each form domain. The aim of
this initiative is similar to ours concerning the identifica-
tion of most frequently used data elements for clinical tri-
als. Nevertheless, the focus of our work is different and
goes beyond this initiative in terms of determining the
availability and quality of data within EHR systems.
Köpcke et al. have analyzed eligibility criteria from 15
clinical trials and determined the presence and complete-
ness within the partners EHR systems [33]. Botsis et al. ex-
amined the incompleteness rate of diagnoses in pathology
reports resulting in 48.2% (1479 missing of 3068 patients)
[25]. Both publications show that re-use of EHR data relies
on the availability of (1) data fields and (2) captured pa-
tient values.
Limitations
This research work aimed to build a data inventory for
CTE and SAE reporting within the IMI funded EHR4CR
project. Therefore, the inventory represents data elements
that are important for trials conducted by European
pharmaceutical companies as well as showing the avail-
ability and frequency within large European university
hospitals. The number of clinical trials in this analysis is
limited since most trial metadata are not publicly available
[34] and EFPIA partners have provided a small number of
clinical trials for the analyzed disease areas. So, this re-
search could be treated as a pilot study and as a founda-
tion for a more comprehensive analysis.
Data exports at the sites have been performed on dif-
ferent sources due to different site specific data access
policies: two sites queried their clinical data warehouses;
four exported data directly from the EHR and because
of permission restrictions two sites did not have the pos-
sibility to access patient data at all. One site was only
able to export data from a dedicated system for one
clinic. The time period for data analyses was the year
2013. At one site data for 2013 was not available in the
data warehouse, so, they chose 2012 for their queries.
Another site was only able to take the first half of the
year for exports. It includes in-patients as well as out-
patients (apart from one site) for all medical disciplines
available in the source systems.
The data exports of this research represent only data of
nine university hospitals across Europe. The generalizability
of this approach relies on several aspects: First of all
the adoption of EHR systems is a crucial indicator
whether data could be made electronically available. The
degree of digitalization is also a key factor. Although an
electronic system is available it is not necessarily being
used. Often, paper is still used in parallel. Last but not
least, the degree of structuredness plays an essential role
as to whether data is eligible for re-use.
Data elements in clinical trials are highly standardized
and EHR documentation forms often contain unstructured
information as free text, notwithstanding, initiatives or
tools like openEHR [35] or Clinical Element Model [36]
aim at defining standardized data elements for clinical
documentation. Even though projects like SHARPn
[37] or cloud4health [38] use natural language process-
ing techniques for extracting relevant information from
free text documents, the EHR4CR project did not focus
on this approach.
Further research
Several pharmaceutical companies have private data stan-
dards catalogs of forms which are used to create CRFs for
clinical trials. Such catalogues ensure that a clinical trial
doesn’t have to start from scratch when setting up a new
trial. In this regard, the pharmaceutical companies may
benefit from each other when using a standardized catalog
of data elements in certain areas together.
A further step for the EHR4CR project is the introduc-
tion of the CTE platform within the overall infrastructure.
Consequently, the approach of electronic data exchange
from patient care to clinical research has to be evaluated.
It is also worthwhile to examine whether the application
of the EHR4CR platform generates the desired advan-
tages and savings for both sides: time saving and error-
reductions for study nurses/sites and reduced SDV as
well as more rapidly conducted data documentation for
the industry or academic researchers. Reduced expend-
iture of time for SDV and data collection enables to focus
more on other value added activities such as training and
recruitment.
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Similar to this work, most of the researches focus on
the availability and quality of routinely collected patient
data. However, it remains unclear whether the available
common data elements are exactly the required elements
for a clinical trial and whether the procedure of documen-
tation satisfies the needs. For instance, the timeliness and
the relationship between data elements play essential
roles. The identification of suitable EHR data elements
have been performed in all conscience, but the context of
documentation remains at times unknown and is also
controversially discussed in the literature [10, 39].
Further investigations concerning the data quality and
the purpose of documentation are essential to ensure
that correct data elements are selected for the secondary
use of patient care data, in particular for a clinical trial
execution, and that their contribution toward monitoring
of therapeutic efficacy, patient-safety and cost-effectiveness
can be clearly assessed.
Conclusions
Common data elements in clinical trials have been identi-
fied and their availability in hospital systems elucidated.
Several elements, often those related to reimbursement,
are frequently available whereas more specialized elements
are ranked at the bottom of the data inventory list. Hospi-
tals that want to obtain the benefits of reusing data for re-
search from their EHR are now able to prioritize their
efforts based on this common data element list.
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